1. Proceedings of the International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use: Tripartite guideline, S6: Preclinical Safety Evaluation Of Biotechnology-Derived Pharmaceuticals, July 1997
2. Committee for Medicinal Products (CHMP) For Human Use: Concept paper on immunogenicity assessment of therapeutic proteins, February 2006, EMEA/CHMP/BMWP/246511/2005
3. D. J. Snodin, and P. R. Ryle. Understanding and applying regulatory guidance on the nonclinical development of biotechnology-derived pharmaceuticals. Biodrugs.
20(1):25–52 (2006).
4. E. Koren, L. A. Zuckerman, and A. R. Mire-Sluis. Immune responses to therapeutic proteins in humans—clinical significance, assessment and prediction. Curr. Pharm. Biotechnol. 3:349–360 (2002).
5. A. S. Rosenberg, and A. Worobec. A risk-based approach to immunogenicity concerns of therapeutic protein products, part 1: considering consequences of the immune response to a protein. BioPharm. Int. 17:22–26 (2004).